Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
Nicola J. Curtis(AstraZeneca (United Kingdom)), Susan E. Critchlow(AstraZeneca (United Kingdom))
Cited by 155
Related Papers
A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs
|Molecular Systems Biology|2022|36
Epithelial-mesenchymal transition is the main driver of intrinsic metabolism in cancer cell lines
|bioRxiv (Cold Spring Harbor Laboratory)|2021|2